MRNA — Moderna, Inc.

Summary of Moderna's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $400 million, a significant increase of $300 million year-over-year, primarily driven by international sales under long-term partnerships.
• Net Loss: $1.3 billion on a GAAP basis ($3.40 per share), which includes an $878 million litigation settlement. Excluding this, the adjusted net loss was $0.5 billion ($1.18 per share), down over 50% from the previous year.
• Cash Position: $7.5 billion in cash and investments, down from $8.1 billion at the end of 2025, primarily due to operating losses.
• Cost Reduction: Achieved a 26% year-over-year reduction in adjusted cash costs, maintaining a target of approximately $4.2 billion for the full year.

2. Strategic Updates and Business Highlights

• Product Approvals: Received EU approval for the first flu plus COVID combination vaccine (mCOMBRIAX) and mNEXSPIKE, marking a significant milestone with four approved products.
• Clinical Trials: Initiated a Phase III trial for Intismeran in non-small cell lung cancer and presented new data for mRNA-4359 at AACR.
• Partnerships: Continued execution of strategic partnerships, particularly with the UK government, contributing to strong international revenue.

3. Forward Guidance and Outlook

• 2026 Revenue Growth: Reiterated guidance for up to 10% revenue growth, with expectations of $50 million to $100 million in Q2 revenue, split evenly between U.S. and international markets.
• Cost of Sales: Projected to increase to $1.8 billion due to the litigation settlement, but gross margin improvements are anticipated from manufacturing efficiencies.
• R&D and SG&A Expenses: Expected to remain around $3 billion and $1 billion, respectively, with a focus on maintaining financial discipline.

4. Bad News, Challenges, or Points of Concern

• Litigation Settlement: The $950 million settlement payment is due in Q3 2026, with potential additional payments of up to $1.3 billion depending on the outcome of ongoing legal proceedings.
• Market Risks: Anticipated declines in COVID vaccination rates could impact revenue, although this is expected to be offset by growth from new products and partnerships.
• Geopolitical Concerns: While no immediate impacts from the Middle East conflict were noted, the company will continue to monitor geopolitical developments.

5. Notable Q&A Insights

• Intismeran Strategy: The decision to pursue a Phase III trial for Intismeran as a monotherapy in early-stage lung cancer was discussed, emphasizing the potential to prevent recurrence in high-risk patients.
• U.K. Orders: Clarified that the strong Q1 sales included deliveries for the U.K.'s spring campaign, with expectations for a fall campaign as well.
• Regulatory Interactions: The company remains optimistic about the upcoming PDUFA date for its flu vaccine, with ongoing positive interactions with the FDA.
• Market Access for New Products: The commercialization strategy for the new combination vaccine focuses on securing market access and demonstrating economic value to healthcare systems, with a successful launch anticipated in 2027.

Overall, Moderna reported a strong start to 2026, with significant revenue growth and strategic advancements in its product pipeline, despite facing challenges related to litigation and market dynamics.